1. Lugtenberg M, Burgers JS, Westert GP: Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. Quality and Safety in Health Care 2009, 18(5):385.
2. Jano E, Aparasu RR: Healthcare Outcomes Associated with Beers' Criteria: A Systematic Review. Annals of Pharmacotherapy 2007, 41(3):438-448.
3. Motter FR, Fritzen JS, Hilmer SN, Paniz É V, Paniz VMV: Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol 2018, 74(6):679-700.
4. Renom-Guiteras A, Meyer G, Thürmann PA: The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol 2015, 71(7):861-875.
5. OCEBM Levels of Evidence Working Group*. “The Oxford Levels of Evidence 2”. Oxford Centre for Evidence-Based Medicine. https://www.cebm.net/index.aspx?o=5653. In.
6. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, deBeer H et al: GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011, 64(4):383-394.
7. Hodkinson A, Kirkham JJ, Tudur-Smith C, Gamble C: Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open 2013, 3(9):e003436.
8. Jia P, Lin L, Kwong JSW, Xu C: Many meta-analyses of rare events in the Cochrane Database of Systematic Reviews were underpowered. Journal of Clinical Epidemiology 2021, 131:113-122.
9. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J: A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 2015, 16(1):495.
10. Luo J, Eldredge C, Cho CC, Cisler RA: Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data. JMIR Med Inform 2016, 4(4):e30.
11. Peryer G, Golder S, Junqueira D, Vohra S, Loke YK. Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from In.
12. Holt S, Schmiedl S, Thürmann PA: Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 2010, 107(31-32):543-551.
13. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S et al: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64(4):401-406.
14. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, Morgan RL, Gartlehner G, Kunz R, Katikireddi SV et al: GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol 2019, 111:105-114.
15. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y et al: GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol 2011, 64(4):407-415.
16. Jüni P, Loke Y, Pigott T, Ramsay C, Regidor D, Rothstein H, Sandhu L, Santaguida P, Schünemann H, Shea B: Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance. Br Med J 2016.
17. Quigley JM, Thompson JC, Halfpenny NJ, Scott DA: Critical appraisal of nonrandomized studies-A review of recommended and commonly used tools. J Eval Clin Pract 2019, 25(1):44-52.
18. Sanderson S, Tatt ID, Higgins JP: Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007, 36(3):666-676.
19. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G et al: GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011, 64(12):1283-1293.
20. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P, Djulbegovic B, Atkins D, Falck-Ytter Y et al: GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol 2011, 64(12):1277-1282.
21. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ: Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ : British Medical Journal 2014, 349:g6501.
22. Rodgers MA, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Simmonds MC, Stewart LA: Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ : British Medical Journal 2013, 346:f3981.
23. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins D, Kunz R, Brozek J, Montori V et al: GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011, 64(12):1311-1316.
24. Bross ID: Pertinency of an extraneous variable. Journal of chronic diseases 1967, 20(7):487-495.
25. Fewell Z, Davey Smith G, Sterne JAC: The Impact of Residual and Unmeasured Confounding in Epidemiologic Studies: A Simulation Study. American Journal of Epidemiology 2007, 166(6):646-655.
26. Kuss O, Miller M: Unknown confounders did not bias the treatment effect when improving balance of known confounders in randomized trials. J Clin Epidemiol 2020, 126:9-16.
27. Glasziou P, Chalmers I, Rawlins M, McCulloch P: When are randomised trials unnecessary? Picking signal from noise. BMJ 2007, 334(7589):349-351.
28. Sandberg L, Taavola H, Aoki Y, Chandler R, Norén GN: Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase. Drug Safety 2020, 43(10):999-1009.
29. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou P, Jaeschke R, Akl EA et al: GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol 2011, 64(12):1294-1302.
30. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, Gagnier J, Borenstein M, van der Heijden GJMG, Dahabreh IJ et al: Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Canadian Medical Association Journal 2020, 192(32):E901-E906.